Experimental
Column chromatography was performed under gravity, over silica gel 60 (35-70µm) purchased from Merck. Analytical TLC was performed using aluminium-backed plates coated with Kieselgel 60 F 254 , from Merck. The chromatograms were visualised using either UV light (UVGL-58, short wavelength), ninhydrin (acidic) or potassium permanganate (basic). Melting points were carried out using a Reichert-Jung Thermo Galen Kopfler block or a Gallenkamp MFB-595 melting point apparatus and are uncorrected. High and low resolution electron impact (EI) mass spectra were recorded using EI ionisation at 70eV, on a VG AutoSpec instrument, equipped with a Fisons autosampler. 1 H NMR and 13 C NMR spectra were recorded using a JEOL 270 (operating at 270 MHz for 1 H and 67.8 MHz for 13 C) spectrometer. Chemical shifts (δ) are measured in ppm. Spectra were referenced internally using TMS as the standard. Only diagnostic peaks have been quoted for proton NMR. Microanalysis was performed with a Perkin-Elmer 240C analyser. Infrared spectroscopy was performed on either a Perkin-Elmer 782 Instrument. Chemicals and solvents were purchased from Aldrich chemical company. Compounds were submitted for testing as their oxalate salts, formed by adding one equivalent of oxalic acid to an ethanolic solution of the ligand. Ligands were > 95% pure by microanalysis.
N-Cyclopropylmethyl-7,8-dihydro-14β β β β-[3'-(methoxycarbonyl)propenamido]normorphinone (2a)
A suspension of 14β-amino-N-cyclopropylmethyl-7,8-dihydronormorphinone (8) 
propenamido]normorphinone oxalate (2a) (203 mg, 0.35 mmol) and 10% Pd/C (150 mg) in CH 3 OH (30 mL) was hydrogenated at 15 psi until H 2 uptake ceased. The catalyst was removed by filtration through celite and the filtrate evaporated. The residue was purified by column chromatography (CH 2 Cl 2 :CH 3 OH, 19:1) to give 6 as a clear oil (98 mg, 62%). IR (CHCl 3 ) 3562, 3325, 1726, 1672 cm -1 ; 1 H nmr δ 0.20 (2H, m, NCH 2 CH(CHHCHH)), 0.54 (2H, m, NCH 2 CH(CHHCHH)), 0.85 (1H, m, NCH 2 CH(CH 2 CH 2 )), 3.70 (3H, s, OCH 3 ), 4.85 (1H, s, H-5), 6.58 (1H, d, J 10Hz, Aryl-H), 6.72 (1H, d, J 10Hz, Aryl-H), 7.16 (1H, s, NH); 13 C nmr δ 3.7, 4. 1, 9.3, 21.6, 29.2, 29.7, 31.5, 34.5, 36.8, 44.3, 48.6, 51.9, 56.3, 59.3, 59.9, 89.7, 118.1, 119.6, 124.1, 128.3, 139.1, 143.6, 172.6, 173.6, 208. (10) A solution of 3-O-(tert-butyldimethylsilyl)naltrexone (9) 25 (690 mg, 1.5 mmol) and monomethyl fumaroyl anhydride (630 mg, 2.60 mmol) in dry toluene (12 mL) was heated to reflux under N 2 for 3 h. After cooling the reaction mixture was washed with dilute NaHCO 3 (aq.) (2 x 5 mL) and water (5 mL), dried (MgSO 4 ), filtered and the solvent evaporated. The residue was purified by silica gel column chromatography (CH 2 Cl 2 :CH 3 OH, 49:1) to yield () as a pale yellow solid (597 mg, 69%). IR (CHCl 3 ) 1715 cm -1 ; 1 H nmr δ 0.03 (2H, m, NCH 2 CH(CHHCHH)), 0.19 (3H, s, SiCH3), 0.29 (3H, s, SiCH3), 0.45 (2H, m, NCH 2 CH(CHHCHH)), 0.68 (1H, m, NCH 2 CH(CH 2 CH 2 )), 1.01 (9H, s, 3 x CH 3 ), 3.83 (3H, s, OCH 3 ), 4.72 (1H, s, H-5), 6.56 (1H, d, J 10 Hz, Aryl-H), 6.65 (1H, d, J 10Hz, Aryl-H), 6.90 (1H, d, J 16Hz ), 6.99 (1H, d, J 16Hz); 13 C nmr  -4.7, -4.5, 3.8, 3.9, 9.5, 18.2, 23.2, 25.7, 26.9, 30.4, 35.5, 43.8, 51.0, 52.3, 55.2, 59.2, 84.1, 89.4, 119.3, 122.6, 126.0, 128.4, 133.0, 135.1, 138.0, 146.7, 163.6, 165.4, 206.4 ; EIMS 567 (M+, 99%); Anal. (oxalate salt) (C 31 H 41 NO 7 Si) C, H, N.
N-Cyclopropylmethyl-7,8-dihydro-14β β β β-[3'-(methoxycarbonyl)propenoyloxy]normorphinone (3a)
A solution of 3-O-(tert-butyldimethylsilyl)-N-cyclopropylmethyl-7,8-dihydro-14β-[3'-(methoxycarbonyl)propenoyloxy]normorphinone (10) (570 mg, 1.00 mmol) and 6M HCl (1.2 mL) in methanol (12 mL) was stirred at RT for 1 h, then neutralised (NaHCO 3 ) and all solvents then removed in vacuo. The residue was dissolved in CH 2 Cl 2 , filtered, dried (MgSO 4 ), filtered and the solvent again removed in vacuo. Silica gel chromatography (CH 2 Cl 2 :CH 3 OH, 24:1) yielded 3a as a clear oil (166 mg, 37%). IR (CHCl 3 ) 3567, 1723 cm -1 ; 1 H nmr δ 0.05 (2H, m, NCH 2 CH(CHHCHH)), 0.48 (2H, m, NCH 2 CH(CHHCHH)), 0.72 (1H, m, NCH 2 CH(CH 2 CH 2 )), 3.82 (3H, s, CH3), 4.98 (1H, s, H-5), 6.62 (1H, d, J 10Hz, Aryl-H), 6.76 (1H, d, J 10Hz, Aryl-H), 6.92(1H, d, J 16Hz), 7.02 (1H, d, J 16Hz); 13 C nmr δ 3.7, 4. 0, 9.27, 23.1, 25.7, 27.0, 30.0, 35.6, 43.9, 51.2, 55.3, 59.2, 84.1, 89.9, 118.5, 120.0, 124.5, 127.9, 133.0, 135.1, 139.2, 143.5, 163.7, 165.5, 208.5; EIMS 453 (M+, 100%); Anal. (oxalate salt) (C 27 H 29 NO 11 .3H 2 O) C, N, requires H 5.90, found H 5.32. N-Cyclopropylmethyl-6,14-endoethano-7α α α α-(methoxyfumaroylamino)tetrahydronororipavine (4a)
To a solution of 7α-amino-N-cyclopropylmethyl-6,14-endoethanotetrahydronororipavine (11a) (0.43 g, 1.1 mmol) in dry CH 2 Cl 2 (100 mL) was added triethylamine (0.45 g, 4.5 mmol). To this mixture, under N 2 , was added a solution of methyl-(3-chloroformyl)acrylate (0.16 g, 1.1 mmol) in CH 2 Cl 2 (10 mL) dropwise over 45 min, stirring was continued for 1 h before removal of the solvent in vacuo. Purification by column chromatography (CH 2 Cl 2 :CH 3 OH:NH 3 (conc.), 94:5:1) gave 4a (0.35 g, 63%); IR (CHCl 3 ) 3410, 1723 cm -1 ; 1 H nmr δ 0.08 (2H, m, NCH 2 CH(CHHCHH)), 0.45 (2H, m, NCH 2 CH(CHHCHH)), 3.33 (3H, s, CO 2 CH 3 ), 3.82 (3H, s, 6-OCH 3 ), 4.60 (1H, s, H-5), 6.52 (1H, d, J 8Hz, 1-H), 6.70 (1H, d, J 8Hz, 2-H), 6.89 (1H, d, J 16Hz, C=CH), 7.11 (1H, d, J 16Hz, C=CH); 13 C nmr δ 3. 6, 3.7, 9.3, 19.8, 22.8, 28.6, 35.0, 35.4, 37.1, 43.4, 45.6, 45.9, 49.8, 52.3, 58.4, 59.9, 76.3, 76.9, 87.9, 117.1, 119.8, 127.4, 129.7, 132.0, 137.0, 137.8, 145.6, 163.8, 166.7 
N-Cyclopropylmethyl-6,14-endoethano-7α α α α-(methoxyfumaroylaminomethyl)tetrahydronororipavine (5a)
A solution of 7α-aminomethyl-N-cyclopropylmethyl-6,14-endoethano-tetrahydronororipavine (11b) 4 (0.22g, 0.55 mmol) was treated as described for 4a (above) to yield, after column chromatography (CH 2 Cl 2 :CH 3 OH:NH 3 (conc.), 94:5:1) 5a (0.13 g, 48%); IR (CHCl 3 ) 
